Placebo to Zoledronic Acid

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, Amgen

Conditions

Bone MetastasesCancerHematologic MalignanciesMultiple MyelomaMultiple Myeloma Bone LesionsNon-Small Cell Lung CancerOncologyPaget's Disease of Bone

Phase 2

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

CompletedNCT01951586

AmgenNon-Small Cell Lung Cancer

Start: 2013-12-31End: 2017-11-28Updated: 2021-10-25

Phase 3

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

CompletedNCT00051636

Novartis PharmaceuticalsPaget's Disease of Bone

Start: 2001-01-31End: 2011-04-30Updated: 2012-05-15

Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period

CompletedNCT00103740

Novartis PharmaceuticalsPaget's Disease of Bone

Start: 2002-04-30End: 2011-04-30Updated: 2012-06-04

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

CompletedNCT01345019

AmgenBone Metastases, Cancer, Hematologic Malignancies +3

Start: 2012-05-17End: 2019-03-29Updated: 2022-11-08

Phase 4

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

CompletedNCT01732770

AmgenPost Menopausal Osteoporosis

Start: 2012-11-07End: 2015-01-07Updated: 2020-03-10

Related Papers

Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study

Blood Advances2021-02-0241 citations

Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.

2020-06-1011 citations

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.

2019-11-2844 citations

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

2018-02-09302 citations

Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease.

Journal of Clinical Oncology2017-05-2012 citations

Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial.

Journal of Clinical Oncology2015-05-20

A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.

Journal of Clinical Oncology2014-05-201 citations

A randomized, double-blind, multicenter phase 2 trial of denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer.

Journal of Clinical Oncology2014-05-201 citations